Studies on the effects of glucose in vitro and of the glycaemic state in vivo on the binding characteristics of mu, delta and kappa opiate receptors in mouse brain

The role of nitric oxide in diabetes-induced changes of morphine tolerance in rats

Several neuroendocrine complications including diabetes change the morphine antinociception and the development of tolerance to the drug. Morphine antinociception was reduced significantly in morphine tolerant diabetic rats compared to the non-diabetic animals. The exact mechanism of this effect is not known. This study was performed to determine the role of nitric oxide (NO) on morphine tolerance in diabetic state. Nociceptive responses in alloxan-induced diabetic morphine tolerated rats were measured by the hot-plate test. The urinary nitric oxide level was measured spectrophotometrically with Griess reagent. For the conversion of nitrate to nitrite, vanadium chloride was used. The results showed that experimental diabetes increased morphine analgesia. Conversely, degree of tolerance to morphine was diminished in diabetic state. The urinary nitrite content in diabetic morphine tolerated rats was higher than non-diabetic groups. L-arginine significantly increased the NO production in diabetic morphine tolerated animals, whereas aminoguanidine decreased it. Appropriately, L-arginine increased the latency time of reaction to noxious stimuli in diabetic compared to non-diabetic rats. L-arginine-treated animals also showed more tolerance to morphine analgesia. As expected, aminoguanidine deducted the level of morphine tolerance in diabetic animals. It is suggested that NO has a modulatory role in the effects of diabetes on morphine analgesia and tolerance.

Sugar Solution Analgesia: The Effects of Glucose on Expressed Mu Opioid Receptors

Glucose or sucrose solutions administered orally provide effective analgesia for procedural pain in neonates. Because analgesia with sugar solutions can be decreased by opioid receptor antagonists, we tested the hypothesis that glucose directly activates opioid receptors. Mu opioid receptors (MOR-1) were expressed in Xenopus oocytes, a well recognized expression system, and glucose was tested for possible agonist, antagonist, and modulatory effects on the receptor. In control experiments, 10 nM of Tyr-D-Ala-Gly-Me-Phe-Gly-ol (DAMGO), a synthetic enkephalin and specific mu agonist, activated the MOR-1, whereas 20 mM of glucose had no effect. In addition, glucose had no effect on the activation of the mu receptor by DAMGO. Finally, glucose did not modulate acute receptor desensitization induced by DAMGO. We conclude that glucose does not directly interact with MOR-1 in an in vitro expression system and that the purported interaction between glucose and the opioid system may be an indirect one, involving release of endogenous opioids.

Cocaine and κ-opioid withdrawal in Planaria blocked by d-, but not l-, glucose

Planarians (Dugesia dorotocephala) that were exposed for 1 h to cocaine (80 microM) or to the kappa-selective opioid receptor agonist U-50,488H (1 microM) displayed an abstinence-induced withdrawal syndrome, indicative of the development of physical dependence, when they were tested in cocaine- (or U-50,488H-) free water, but not when they were tested in cocaine- (or U-50,488H-) containing water. The withdrawal was manifested as a significant (P<0.05) decrease in the rate of planarian spontaneous locomotor activity over a 5-min observation period, using a recently designed metric. Co-exposure of the planarians to D-glucose (1 microM) or to 2-deoxy-D-glucose (2-DG, 1 microM), but not to L-glucose (1 microM), significantly attenuated (P<0.05) the development of physical dependence, shown by an attenuated withdrawal syndrome, from cocaine and U-50,488H. These results suggest that either D-glucose and 2-deoxy-D-glucose compete with a common cocaine and kappa-opioid transport mechanism or that the development of physical dependence (or the inhibition of abstinence-induced withdrawal) in planarians requires energy supplied from glucose metabolism.

ATP-sensitive potassium channel blockade enhances spontaneous alternation performance in the rat: a potential mechanism for glucose-mediated memory enhancement

Peripheral and central injections of D-glucose enhance learning and memory in rats, and block memory impairments produced by morphine. The mechanism(s) for these effects is (are) as yet unknown. One mechanism by which glucose might act on memory and other brain functions is by regulating the ATP-sensitive potassium channel. This channel may couple glucose metabolism and neuronal excitability, with channel blockade increasing the likelihood of stimulus-evoked neurotransmitter release. The present experiments explored the effects of intra-septal injections of glucose and the ATP-sensitive potassium channel blocker glibenclamide on spontaneous alternation behavior in the rat. Intra-septal injections of glucose (20 nmol) or glibenclamide (10 nmol), 30 min prior to plus-maze spontaneous alternation performance, significantly enhanced alternation scores compared to rats receiving vehicle injections. Glibenclamide enhanced spontaneous alternation performance in an inverted-U dose-response manner. Individually sub-effective doses of glucose (5 nmol) and glibenclamide (5 nmol) significantly enhanced plus-maze alternation scores when co-injected into the septal area. Glibenclamide (10 nmol), when co-administered with morphine (4 nmol) 30 min prior to Y-maze spontaneous alternation performance, attenuated the performance-impairing effects of morphine alone. The present findings show that intra-septal injections of the direct ATP-sensitive potassium channel blocker glibenclamide, both alone and in conjunction with a sub-effective dose of glucose, enhance spontaneous alternation performance and attenuate the performance-impairing effects of morphine. The similarity of the results obtained with glibenclamide and glucose, together with their similar actions on ATP-sensitive potassium channel function, suggests that glucose may modulate memory-dependent behavior in the rat by regulating the ATP-sensitive potassium channel.

Diabetes alters mu and kappa opioid binding in rat brain regions: comparison with effects of food restriction

Diabetic rats display changes in opioid pharmacology and brain regional levels of opioid peptides and prodynorphin mRNA. Previous investigations of opioid receptor binding, carried out in whole-brain homogenates, have, however, failed to detect changes. In the present study, quantitative autoradiography was used to measure mu and kappa opioid receptor binding in discrete brain regions of streptozotocin-treated diabetic rats. Measurement was limited to regions that previously displayed opioid binding changes in chronically food-restricted rats, since our primary aim is to identify brain mechanisms that mediate adaptive responses to persistent metabolic need and adipose depletion. Diabetics displayed strong trends or statistically significant changes which matched seven of the thirteen binding changes observed in food-restricted rats. In no case did diabetics display changes in the opposite direction. The two statistically significant changes common to food-restricted and diabetic rats are increased kappa binding in the medial preoptic area and decreased mu binding in the lateral habenula. The possible functional significance of these changes is discussed.

The reduction of antinociceptive effect of morphine administered intraventricularly is correlated with the decrease of serotonin release from the spinal cord in streptozotocin-induced diabetic rats

1. The antinociceptive effect of morphine (25 micrograms) administered into the 3rd ventricle was significantly attenuated in streptozotocin-induced diabetic rats as measured by the tail-flick assay. 2. The release of serotonin (5-HT; 5-hydroxytryptamine) from the spinal cord caused by intraventricular injection of morphine (25 micrograms) was significantly reduced in streptozotocin-induced diabetic rats. 3. No differences of 5-HT contents of the spinal cord (lumbar cord) between streptozotocin-induced diabetic- and vehicle-treated rats were found. 4. It is concluded that the reduction of antinociception produced by intraventricular injection of morphine in streptozotocin-induced diabetic rats might be, at least partly, due to the decrease of 5-HT release from the spinal cord.

Effects of streptozotocin-induced diabetes on prodynorphin-derived peptides in rat brain regions

Pharmacological studies suggest that diabetes produces changes in the brain opioid system, affecting several behavioral functions including analgesia, feeding and self-stimulation. Previous investigations of opioid receptor binding have failed to explain the unusual opioid pharmacology of the diabetic animal. In the present study, the effects of streptozotocin-induced diabetes on levels of three immunoreactive (ir)-prodynorphin-derived peptides, ir-dynorphin A1-17 (A1-17), ir-dynorphin A1-8 (A1-8) and ir-dynorphin B1-13 (B1-13), were determined in eleven brain regions known to be involved in appetite, taste and reward. Diabetes was found to increase levels of A1-17 in the ventromedial and dorsomedial hypothalamic nuclei (+60% and +25%, respectively) and levels of A1-8 in the dorsomedial and lateral hypothalamus (+45% and +35%, respectively). The possible significance of these results is discussed in relation to (i) diabetic hyperphagia, (ii) medial hypothalamic transduction of circulating insulin levels, and (iii) the potentiation of reward by metabolic need states.

Streptozotocin-induced diabetes produces a naltrexone-reversible lowering of self-stimulation threshold

Stimulation frequency thresholds for lateral hypothalamic self-stimulation were monitored for 3 weeks following the induction of diabetes with streptozotocin (STZ). In each of the 3 weeks following STZ treatment, thresholds of diabetic rats were significantly lower than their pre-STZ baseline while thresholds of control animals did not change. Naltrexone (5.0 mg/kg, s.c.) increased thresholds of diabetic rats while having no effect on thresholds of control rats. These results suggest that STZ-induced diabetes is associated with an opioid-mediated lowering of self-stimulation threshold. The possible relationship between this finding and similar findings obtained in food-restricted animals is discussed.